In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

FOPO nets $170.1mm for Synageva BioPharma

30 Sep 2013

Executive Summary

Orphan disease-focused Synageva BioPharma Corp. netted $170.1mm through the follow-on public offering of 3.16mm common shares (including the overallotment) at $56.63 each. The company will use part of the proceeds to further develop its mucopolysaccharidosis IIIB candidate SBC103, which is expected to enter the clinic in the first half of 2014.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By